Brought to you by:
The 10 most popular Vascular Specialist stories of November 2022
Among November’s most read Vascular Specialist stories were updates from the BEST-CLI trial in the form of new data and funding; a guest editorial calling for (better) training vis-à-vis counseling patients about their treatment options; news of positive results from…
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint target of 54%, chief investigator Daniel Clair, MD, told the 2022 Vascular Interventional Advances (VIVA) meeting…
Treating PAD: ‘Run, don’t walk, to sign up for this incredible course’
No matter if you’re a surgeon with a few years—or a few decades—of experience, faculty members of a new, upcoming Society for Vascular Surgery course say you’re sure to learn valuable skills and strategies to help in treating patients with…
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called “no-option” chronic limb-threatening ischemia (CLTI) patients, the eponymous device maker announced today. “The PROMISE II investigators are…
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for both amputation-free survival and wound healing, a press release reports. The late-breaking data were presented at…
LimFlow system a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous deep vein arterialization (pDVA) with the LimFlow system offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent study published in the Journal of Critical Limb Ischemia. Peter Schneider, MD, professor of surgery at…
One-year results from PROMISE I study of LimFlow system in ‘no-option’ CLTI patients published
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been published in the Journal of Vascular Surgery. Results showed sustained positive outcomes for both amputation-free survival and…
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialization (pDVA) system. Results were published online yesterday in the Journal of Endovascular Therapy and will also appear in the August print issue…